AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8227867 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐Test device
Number of subjects: 0
Study 8227867 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaPIK device
Number of subjects: 0
Study 8227867 — intervention group
Group type: COMPARATOR
Intervention: Saline control sites
Number of subjects: 0
Study 8227867 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall observation
Number of subjects: 0
Study 3528436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum cytological screening every 4 months combined with chest roentgenography (yearly or every 4 months)
Number of subjects: 0
Study 3528436 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest roentgenography
Number of subjects: 0
Study 3528436 — intervention group
Group type: COMPARATOR
Intervention: Both sputum cytology and chest roentgenography every 4 months
Number of subjects: 0
Study 29851090 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) in addition to conventional therapy (compression garments, massage therapy, exercise) for 6 weeks; treatment details: wavelength 980/810 nm (80:20 ratio), output power 500 mW, beam spot size 5 cm2, irradiance 100 mW/cm2, treatment time per area 1 minute, total dosage delivered 300 J.
Number of subjects: 17
Study 29851090 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (compression garments, massage therapy, exercise).
Number of subjects: 17
Study 27404064 — intervention group
Group type: EXPERIMENTAL
Intervention: incentaHEALTH (INCENT; incentivized individually targeted Internet‐based intervention)
Number of subjects: 1460
Study 27404064 — intervention group
Group type: COMPARATOR
Intervention: Livin' My Weigh (LMW; less‐intense quarterly newsletters)
Number of subjects: 1460
Study 24236667 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation through a tubular retractor via the Wiltse approach
Number of subjects: 39
Study 24236667 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation via the posterior midline approach
Number of subjects: 39
Study 22395260 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg midazolam
Number of subjects: 60
Study 22395260 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg midazolam
Number of subjects: 60
Study 20863007 — intervention group
Group type: EXPERIMENTAL
Intervention: Test FDC (rabeprazole 20 mg and diclofenac sodium 100 mg)
Number of subjects: 0
Study 20863007 — intervention group
Group type: COMPARATOR
Intervention: Reference FDC (rabeprazole 20 mg and diclofenac sodium 100 mg)
Number of subjects: 0
Study 18446720 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor activity
Number of subjects: 811
Study 18446720 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 811
Study 18446720 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor activity
Number of subjects: 811
Study 15745762 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% (twice daily)
Number of subjects: 190
Study 15745762 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% (twice daily)
Number of subjects: 190
Study 12502976 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 12502976 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 30
Study 11054909 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and thienopyridines (specific dosages and duration not mentioned)
Number of subjects: 0
Study 11054909 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer and more potent antiplatelet agents (specific agents not mentioned)
Number of subjects: 0
Study 11054909 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of antiplatelet therapy with aspirin and thienopyridines
Number of subjects: 0
Study 8842505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanterinone 2 mg
Number of subjects: 14
Study 8842505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31718358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 63
Study 31718358 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 63
Study 30497837 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 µg hemagglutinin per strain (FluArt, Hungary)
Number of subjects: 1206
Study 30497837 — intervention group
Group type: COMPARATOR
Intervention: 15 µg hemagglutinin per strain (currently licensed vaccine)
Number of subjects: 1206
Study 29270682 — intervention group
Group type: EXPERIMENTAL
Intervention: Running locked suture technique
Number of subjects: 28
Study 29270682 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture technique
Number of subjects: 28
Study 26747037 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily smoking
Number of subjects: 11140
Study 26747037 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 11140
Study 26747037 — intervention group
Group type: COMPARATOR
Intervention: Never smoking
Number of subjects: 11140
Study 26747037 — intervention group
Group type: EXPERIMENTAL
Intervention: Major coronary events
Number of subjects: 11140
Study 24277680 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (0.4 U/kg, single subcutaneous dose)
Number of subjects: 24
Study 23128937 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesitherapy (KT)
Number of subjects: 40
Study 23128937 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES)
Number of subjects: 40
Study 23128937 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesitherapy combined with Electrical Stimulation (KT+ES)
Number of subjects: 40
Study 23128937 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 40
Study 23128937 — intervention group
Group type: EXPERIMENTAL
Intervention: All rehabilitation programs
Number of subjects: 40
Study 18816950 — intervention group
Group type: EXPERIMENTAL
Intervention: PETTLEP imagery
Number of subjects: 32
Study 18816950 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 32
Study 18816950 — intervention group
Group type: EXPERIMENTAL
Intervention: PETTLEP + physical practice
Number of subjects: 32
Study 18816950 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 16390568 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80
Study 16390568 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 80
Study 15023611 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/d vitamin C
Number of subjects: 69
Study 15023611 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/d grape-seed polyphenols
Number of subjects: 69
Study 15023611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin C and polyphenols
Number of subjects: 69
Study 15023611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 69
Study 10731538 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) supplementation during the luteal phase
Number of subjects: 0
Study 10731538 — intervention group
Group type: COMPARATOR
Intervention: Control group (progestin supplementation without E(2))
Number of subjects: 0
Study 9190279 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 272
Study 9190279 — intervention group
Group type: EXPERIMENTAL
Intervention: Plating
Number of subjects: 272
Study 9190279 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 272
Study 9190279 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 272
Study 1491345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of moxisylyte
Number of subjects: 12
Study 1491345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of moxisylyte (two formulations)
Number of subjects: 12
Study 3085257 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate (single high dose)
Number of subjects: 8
Study 3085257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30234925 — intervention group
Group type: EXPERIMENTAL
Intervention: single‐bolus
Number of subjects: 270
Study 30234925 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent‐boluses
Number of subjects: 270
Study 30234925 — intervention group
Group type: EXPERIMENTAL
Intervention: short‐infusion
Number of subjects: 270
Study 26470783 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (7.5 μg)
Number of subjects: 20
Study 26470783 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 24794277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty
Number of subjects: 623
Study 24794277 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty
Number of subjects: 623
Study 23383459 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (scalp acupoint Dingnie Qianxiexian (MS 6) and body acupoints Neiguan (PC 6), Jianyu (LI 15), Sanyinjiao (SP 6), treated once daily for 20 days)
Number of subjects: 110
Study 23383459 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine neurological therapies only)
Number of subjects: 110
Study 20190281 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA-2291 (25, 50, or 100 mg daily for 12 weeks)
Number of subjects: 191
Study 20190281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 20190281 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA-2291
Number of subjects: 191
Study 18525134 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Power
Number of subjects: 20
Study 18525134 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 16543162 — intervention group
Group type: EXPERIMENTAL
Intervention: Novare Enclose PAD
Number of subjects: 197
Study 16543162 — intervention group
Group type: COMPARATOR
Intervention: Standard aortic side-clamp technique
Number of subjects: 197
Study 16543162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 197
Study 14652381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (plant food-based diet with intensive counseling)
Number of subjects: 104
Study 14652381 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study 10822428 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg L-dopa every 24 hours
Number of subjects: 24
Study 10822428 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg L-dopa every 8 hours
Number of subjects: 24
Study 10822428 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg L-dopa every 8 hours
Number of subjects: 24
Study 10822428 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg L-dopa every 24 hours (3 months prolonged treatment)
Number of subjects: 24
Study 10822428 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg L-dopa every 8 hours (3 months prolonged treatment)
Number of subjects: 24
Study 8798095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day catheterization
Number of subjects: 91
Study 8798095 — intervention group
Group type: COMPARATOR
Intervention: 3 days catheterization
Number of subjects: 91
Study 1633900 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygote intrafallopian transfer (ZIFT)
Number of subjects: 157
Study 1633900 — intervention group
Group type: COMPARATOR
Intervention: In vitro fertilization and embryo transfer (IVF‐ET)
Number of subjects: 157
Study 6487442 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane in oxygen
Number of subjects: 51
Study 6487442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl plus nitrous oxide in oxygen
Number of subjects: 51
Study 6487442 — intervention group
Group type: COMPARATOR
Intervention: Enflurane in oxygen
Number of subjects: 51
Study 6487442 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane in oxygen
Number of subjects: 51
Study 31165888 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning
Number of subjects: 99
Study 31165888 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent Conditioning
Number of subjects: 99
Study 31165888 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent Conditioning
Number of subjects: 99
Study 31165888 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Suggestion
Number of subjects: 99
Study 31165888 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study 30200068 — intervention group
Group type: EXPERIMENTAL
Intervention: 80‐kV group with automatic tube current modulation and AIDR 3D algorithm
Number of subjects: 128
Study 30200068 — intervention group
Group type: EXPERIMENTAL
Intervention: 80‐kV group
Number of subjects: 128
Study 30200068 — intervention group
Group type: COMPARATOR
Intervention: 100‐kV group
Number of subjects: 128
Study 26156950 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diet for 4 days followed by ad libitum intake on day 5
Number of subjects: 26
Study 26156950 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum intake on day 5
Number of subjects: 26
Study 26156950 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater fiber intake
Number of subjects: 26
Study 26156950 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent of energy from saturated fat
Number of subjects: 26
Study 26156950 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percent of energy from sugar
Number of subjects: 26
Study 26156950 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percent of energy from other carbohydrates not considered sugar or fiber
Number of subjects: 26
Study 24139977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted cognitive behaviour therapy (CBT-HA group)
Number of subjects: 444
Study 24139977 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 444
Study 24139977 — intervention group
Group type: COMPARATOR
Intervention: Adapted cognitive behaviour therapy (CBT-HA group) and Standard care
Number of subjects: 444
Study 23759035 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided online sleep training based on Cognitive Behavioral Therapy for insomnia.
Number of subjects: 128
Study 23759035 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control condition.
Number of subjects: 128
Study 20116286 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Number of subjects: 28
Study 20116286 — intervention group
Group type: COMPARATOR
Intervention: Non-chemoembolization (Control)
Number of subjects: 28
Study 18670242 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake (highest quartile)
Number of subjects: 413
Study 17127828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine at 100 mg/daily orally for 52 weeks
Number of subjects: 59
Study 17127828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine at 100 mg/die plus alpha-interferon at 6 MU subcutaneously three times weekly for 52 weeks
Number of subjects: 59
Study 17127828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (lamivudine plus alpha-interferon) for 40 weeks after pre-treatment with lamivudine for 12 weeks
Number of subjects: 59
Study 12623499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 0
Study 11908357 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Maximum Strength Toothpaste (5.0% potassium nitrate and 0.454% stannous fluoride in a silica base)
Number of subjects: 121
Study 11908357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensodyne Fresh Mint Toothpaste (5.0% potassium nitrate and 0.243% sodium fluoride in a silica base)
Number of subjects: 121
Study 11908357 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Winterfresh Gel (0.243% sodium fluoride in a silica base)
Number of subjects: 121
Study 8999672 — intervention group
Group type: EXPERIMENTAL
Intervention: Russian hepatitis B Combiotech vaccine (20 mg)
Number of subjects: 0
Study 8999672 — intervention group
Group type: COMPARATOR
Intervention: Recombivax‐HB vaccine (10 mg)
Number of subjects: 0
Study 1443845 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride (two sprays, 15 minutes before therapy)
Number of subjects: 60
Study 1443845 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control group, two sprays, 15 minutes before therapy)
Number of subjects: 60
Study 1443845 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride
Number of subjects: 60
Study 1443845 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control group)
Number of subjects: 60
Study 2861880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 17354
Study 2861880 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17354
Study 2861880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17354
Study 29440132 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threshold (LT) intervention (ventricular index (VI) >p97 and anterior horn width (AHW) >6 mm)
Number of subjects: 126
Study 29440132 — intervention group
Group type: COMPARATOR
Intervention: Higher threshold (HT) intervention (VI>p97+4 mm and AHW >10 mm)
Number of subjects: 126
Study 30945606 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow cuff
Number of subjects: 183
Study 30945606 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide cuff
Number of subjects: 183
Study 30945606 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher applied pressure
Number of subjects: 183
Study 30945606 — intervention group
Group type: COMPARATOR
Intervention: Lower applied pressure
Number of subjects: 183
Study 30945606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sets 2, 3, and 4
Number of subjects: 183
Study 30945606 — intervention group
Group type: EXPERIMENTAL
Intervention: Echo intensity measurement
Number of subjects: 183
Study 27935660 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX mouthrinses (Group II) used twice a week for 4 months
Number of subjects: 34
Study 27935660 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinses (Group I)
Number of subjects: 34
Study 25971288 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban (LDE)
Number of subjects: 2492
Study 25971288 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2492
Study 25971288 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban (HDE)
Number of subjects: 2492
Study 24186056 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic dissection devices (HDDs)
Number of subjects: 139
Study 24186056 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection technique
Number of subjects: 139
Study 21764407 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 120 U
Number of subjects: 233
Study 21764407 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 240 U
Number of subjects: 233
Study 21764407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 19052155 — intervention group
Group type: EXPERIMENTAL
Intervention: Media literacy education
Number of subjects: 531
Study 16689041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill counts for psychotropic medications
Number of subjects: 72
Study 16689041 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report and informant ratings
Number of subjects: 72
Study 16689041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower medication adherence
Number of subjects: 72
Study 16689041 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Management Administration Assessment (MMAA) role-play
Number of subjects: 72
Study 15160510 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem plus amikacin (20 mg/kg every 8 h plus 15 mg/kg/d in 2 divided doses)
Number of subjects: 33
Study 15160510 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam plus netilmicin (100 mg/4 mg/kg every 8 h plus 7 mg/kg every 24 h)
Number of subjects: 33
Study 11406794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement applied over the posts only (Group A)
Number of subjects: 24
Study 11406794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement introduced into the root canals with a spiral filler and applied over the posts (Group B)
Number of subjects: 24
Study 11406794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement injected into the root canals and then applied over the posts (Group C)
Number of subjects: 24
Study 11406794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement injected into the root canals and a spiral used to spread it into the root canals, and cement applied over the posts (Group D)
Number of subjects: 24
Study 9001768 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% ophthalmic suspension (LE), q.i.d. for 6 weeks
Number of subjects: 220
Study 9001768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (loteprednol etabonate vehicle), q.i.d. for 6 weeks
Number of subjects: 220
Study 8105785 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (one week's treatment)
Number of subjects: 52
Study 8105785 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (two weeks' treatment)
Number of subjects: 52
Study 8105785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one week's treatment)
Number of subjects: 52
Study 3610426 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration only
Number of subjects: 75
Study 3610426 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration-simulation
Number of subjects: 75
Study 3610426 — intervention group
Group type: COMPARATOR
Intervention: Non intervention (control)
Number of subjects: 75
Study 31978740 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral change intervention on handwashing, exclusive breastfeeding before the age of six months, and awareness on diarrhea prevention methods
Number of subjects: 826
Study 31978740 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of safe and adequate water source combined with household water chlorination, and vaccination for rotavirus
Number of subjects: 826
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Children less than six months of age
Number of subjects: 826
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Initiating supplementary feedings before six months of age
Number of subjects: 826
Study 31978740 — intervention group
Group type: COMPARATOR
Intervention: Low educational status of mothers
Number of subjects: 826